Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R21/Matrix-M™ in African Children Living With HIV
NCT05385510Phase 1Completed
- Sponsor
- University of Oxford
- Start
- Jan 2023
- Primary completion
- Sep 2025
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of R21/Matrix-M in malaria (2 arms), sponsored by University of Oxford. Primary endpoints: Solicited local signs and symptoms, Solicited systemic signs and symptoms and 3 more. Started Jan 2023; status: completed.
02
Drugs
R21/Matrix-M
03
Conditions
malaria
Beyond the preview
Go deeper on NCT05385510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05385510.